Secondary analysis of a randomised phase 2 trial plus mouse studies: one dose of mRNA-1283 raised S1-specific CD4+ and CD8+ T-cell responses by day 29 in adults, persisting to day 366 and similar to mRNA-1273 against ancestral, beta and BA.1 strains.
Secondary analysis
Freyn et al. Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies